Alto Neuroscience Stock Quote ANRO - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

4.27

Bid

Ask

Volume

0.00 Day's Range 0.00

3.61 52 Week Range 24.00

Market Cap

115.163M

Previous Close

4.27

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

815,171

Shares Outstanding

26,970,168

Dividend Yield

PE Ratio

-3.17

Earnings Per Share (EPS)

-1.35

Revenue

Net Profit

-36.31M

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.altoneuroscience.com

Headquarters

Wilmington, Delaware, USA

Founded

Alto Neuroscience Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker ANRO. The last closing price for Alto Neuroscience was $4.27. Over the last year, Alto Neuroscience shares have traded in a share price range of $ 3.61 to $ 24.00.

Alto Neuroscience currently has 26,970,168 shares outstanding. The market capitalization of Alto Neuroscience is $115.16 million. Alto Neuroscience has a price to earnings ratio (PE ratio) of -3.17.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – –...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced...

Form 8-K - Current report

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker – – ALTO-100 demonstrated a favorable...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

– Despite its reported benefits for aspects of cognition, vortioxetine does not demonstrate greater clinical efficacy in major depressive disorder (MDD) patients with cognitive impairment– –...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.27	-5.94713656388	4.54	4.8	4.19	341471	4.50253205	CS
4	-0.04	-0.92807424594	4.31	4.98	3.61	719025	4.21174952	CS
12	-7.71	-64.3572621035	11.98	15.04	3.61	815171	7.48936253	CS
26	-7.99	-65.1712887439	12.26	17.55	3.61	467324	8.21021004	CS
52	-17.73	-80.5909090909	22	24	3.61	371852	9.8100071	CS
156	-17.73	-80.5909090909	22	24	3.61	371852	9.8100071	CS
260	-17.73	-80.5909090909	22	24	3.61	371852	9.8100071	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PSBDPalmer Square Capital BDC Inc	$ 22.99 (44.32%)	3
ACRACRES Commercial Realty Corporation	$ 23.99 (43.31%)	9
SNDASonida Senior Living	$ 33.00 (38.83%)	3
SDHYPGIM Short Duration High Yield Opportunities Fund	$ 21.95 (32.63%)	2
SNOWSnowflake Inc	$ 157.00 (21.59%)	316.53k
BTTBlackRock Municipal 2030 Target Term Trust	$ 11.01 (-47.67%)	1
AVNSAvanos Medical Inc	$ 11.01 (-38.39%)	109
SMPStandard Motor Products Inc	$ 20.00 (-36.67%)	102
CBANColony Bankcorp Inc	$ 11.12 (-34.47%)	4
SDHCSmith Douglas Homes Corp	$ 21.00 (-32.78%)	108
NIONIO Inc	$ 4.56 (-1.94%)	323.89k
SNOWSnowflake Inc	$ 157.00 (21.59%)	316.53k
PLTRPalantir Technologies Inc	$ 61.55 (-0.92%)	293.33k
IONQIonQ Inc	$ 28.45 (-1.42%)	277.08k
ZETAZeta Global Holdings Corp	$ 23.72 (2.64%)	200.38k